Publications

Peer-Reviewed Publications

A model-informed clinical trial simulation tool with a graphical user interface for Duchenne muscular dystrophy

Clinical trial simulation
RShiny
Duchenne muscular dystrophy
Middle author
Oct 3, 2024
Kim J, Morales JF, Kang S, Klose M, Willcocks RJ, Daniels MJ, Belfiore-Oshan R, Walter GA, Rooney WD, Vandenborne K, Kim S
CPT: Pharmacometrics & Systems Pharmacology

Type 1 diabetes prevention clinical trial simulator: Case reports of model-informed drug development tool

Clinical trial simulation
RShiny
Type 1 diabetes
Second author
Jul 3, 2024
Morales JF, Klose M, Hoffert Y, Podichetty JT, Burton J, Schmidt S, Romero K, O’Doherty I, Martin F, Campbell-Thompson M, Haller MJ, Atkinson MA, Kim S.
CPT: Pharmacometrics & Systems Pharmacology

Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial

Doxorubicin
TLD-1
PEGylated liposomal doxorubicin
NLME PK
Middle author
Jun 15, 2024
Mc Laughlin AM, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Joerger M, Kloft C.
Cancer Chemotherapy and Pharmacology

Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation

PBPK
Oxycodone
GDI
DDI
UGT2B7
CYP2D6
First author
Mar 1, 2024
Klose M, Cristofoletti R, Silva CM, Mangal N, Turgeon J, Michaud V, Lesko LJ, Schmidt S.
European Journal of Pharmaceutical Sciences

TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16)

TLD-1
PEGylated liposomal doxorubicin
Doxorubicin
Safety
Efficacy
NCA
Middle author
Feb 2, 2024
Colombo I, Koster KL, Holer L, Haefliger S, Rabaglio M, Bastian S, Schwitter M, Eckhardt K, Hayoz S, Mc Laughlin AM, Kloft C, Klose M, Halbherr S, Baumgartner C, Sessa C, Stathis A, Hess D, Joerger M.
European Journal of Cancer

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients

Meropenem
Antiinfectives
NLME PK
Second author
Apr 20, 2021
Liebchen U, Klose M, Paal M, Vogeser M, Zoller M, Schroeder I, Schmitt L, Huisinga W, Michelet R, Zander J, Scharf C, Weinelt FA, Kloft C.
Antibiotics
No matching items

Abstracts/Posters/Presentations